stockrowArrowhead Pharmaceuticals, Inc.
ARWR Healthcare Biotechnology
Arrowhead Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended September 2025) was $829.4 million, up 23,258.2% from fiscal 2024.
- Revenue
- +171.0%
- EPS
- −7.94%
- Free cash flow
- −15.4%
- Total debt
- +259.5%
Quarter to June 2026, against a year earlier
Follow ARWR
Alert me
Arrowhead Pharmaceuticals, Inc. (ARWR) Return on equity
Arrowhead Pharmaceuticals, Inc.'s return on equity over the twelve months to 30 June 2026 was −64.9%, down 64.4 percentage points from fiscal 2025 (−0.47%). Over the past ten years it has ranged from −250.7% (fiscal 2024) to 40.1% (fiscal 2019); the current reading is higher than 91% of that period. That is below the Biotechnology industry median of −50.1% and below the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | −0.47% | 250.25 |
| FY2024 | −250.7% | (192.53) |
| FY2023 | −58.2% | (15.62) |
| FY2022 | −42.6% | (10.21) |
| FY2021 | −32.4% | (8.40) |
| FY2020 | −24.0% | (64.03) |
| FY2019 | 40.1% | 101.91 |
| FY2018 | −61.8% | (22.75) |
| FY2017 | −39.1% | 40.78 |
| FY2016 | −79.9% | (13.15) |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| CYTK Cytokinetics, Incorporated compare | 184.7% |
| CORT Corcept Therapeutics Incorporated compare | 21.7% |
| KRYS Krystal Biotech, Inc. compare | 17.5% |
| PTGX Protagonist Therapeutics, Inc. compare | 11.0% |
| CAI Caris Life Sciences,�Inc. compare | 0.00% |
| MDGL Madrigal Pharmaceuticals, Inc. compare | −24.8% |
| TWST Twist Bioscience Corporation compare | −29.6% |
| SYRE Spyre Therapeutics, Inc. compare | −41.2% |
| ARWR Arrowhead Pharmaceuticals, Inc. | −64.9% |
| Biotechnology industry median | −50.1% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on ARWR
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement